MedPath

Clonidine Hydrochloride

CLONIDINE HYDROCHLORIDE TABLETS USP

Approved
Approval ID

809d8d33-9459-4e74-8cd2-5f5a9670cb95

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 6, 2013

Manufacturers
FDA

Richmond Pharmaceuticals, Inc.

DUNS: 043569607

Products 3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Clonidine Hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code54738-908
Application NumberANDA070924
Product Classification
M
Marketing Category
C73584
G
Generic Name
Clonidine Hydrochloride
Product Specifications
Route of AdministrationORAL
Effective DateJune 29, 2012
FDA Product Classification

INGREDIENTS (6)

Clonidine HydrochlorideActive
Quantity: 0.2 mg in 1 1
Code: W76I6XXF06
Classification: ACTIB
lactoseInactive
Code: J2B2A4N98G
Classification: IACT
magnesium stearateInactive
Code: 70097M6I30
Classification: IACT
cellulose, microcrystallineInactive
Code: OP1R32D61U
Classification: IACT
sodium starch glycolate type a potatoInactive
Code: 5856J3G2A2
Classification: IACT
starch, cornInactive
Code: O8232NY3SJ
Classification: IACT

Clonidine Hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code54738-907
Application NumberANDA070925
Product Classification
M
Marketing Category
C73584
G
Generic Name
Clonidine Hydrochloride
Product Specifications
Route of AdministrationORAL
Effective DateJune 29, 2012
FDA Product Classification

INGREDIENTS (7)

cellulose, microcrystallineInactive
Code: OP1R32D61U
Classification: IACT
lactoseInactive
Code: J2B2A4N98G
Classification: IACT
Clonidine HydrochlorideActive
Quantity: 0.1 mg in 1 1
Code: W76I6XXF06
Classification: ACTIB
starch, cornInactive
Code: O8232NY3SJ
Classification: IACT
D&C Yellow No. 10Inactive
Code: 35SW5USQ3G
Classification: IACT
sodium starch glycolate type a potatoInactive
Code: 5856J3G2A2
Classification: IACT
Aluminum OxideInactive
Code: LMI26O6933
Classification: IACT

Clonidine Hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code54738-909
Application NumberANDA070923
Product Classification
M
Marketing Category
C73584
G
Generic Name
Clonidine Hydrochloride
Product Specifications
Route of AdministrationORAL
Effective DateJune 29, 2012
FDA Product Classification

INGREDIENTS (9)

sodium starch glycolate type a potatoInactive
Code: 5856J3G2A2
Classification: IACT
lactoseInactive
Code: J2B2A4N98G
Classification: IACT
Clonidine HydrochlorideActive
Quantity: 0.3 mg in 1 1
Code: W76I6XXF06
Classification: ACTIB
magnesium stearateInactive
Code: 70097M6I30
Classification: IACT
cellulose, microcrystallineInactive
Code: OP1R32D61U
Classification: IACT
starch, cornInactive
Code: O8232NY3SJ
Classification: IACT
FD&C Blue No. 1Inactive
Code: H3R47K3TBD
Classification: IACT
D&C Yellow No. 10Inactive
Code: 35SW5USQ3G
Classification: IACT
Aluminum OxideInactive
Code: LMI26O6933
Classification: IACT

Drug Labeling Information

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 6/29/2012

ADVERSE REACTIONS

Most adverse effects are mild and tend to diminish with continued therapy. The most frequent (which appear to be dose-related) are dry mouth, occurring in about 40 of 100 patients; drowsiness, about 33 in 100; dizziness, about 16 in 100; constipation and sedation, each about 10 in 100.

The following less frequent adverse experiences have also been reported in patients receiving clonidine hydrochloride tablets USP, but in many cases patients were receiving concomitant medication and a causal relationship has not been established.

**Body as a Whole:**Fatigue, fever, headache, pallor, weakness, and withdrawal syndrome. Also reported were a weakly positive Coombs' test and increased sensitivity to alcohol.

**Cardiovascular:**Bradycardia, congestive heart failure, electrocardiographic abnormalities (i.e., sinus node arrest, junctional bradycardia, high degree AV block and arrhythmias), orthostatic symptoms, palpitations, Raynaud's phenomenon, syncope, and tachycardia. Cases of sinus bradycardia and atrioventricular block have been reported, both with and without the use of concomitant digitalis.

**Central Nervous System:**Agitation, anxiety, delirium, delusional perception, hallucinations (including visual and auditory), insomnia, mental depression, nervousness, other behavioral changes, paresthesia, restlessness, sleep disorder, and vivid dreams or nightmares.

**Dermatological:**Alopecia, angioneurotic edema, hives, pruritus, rash, and urticaria.

**Gastrointestinal:**Abdominal pain, anorexia, constipation, hepatitis, malaise, mild transient abnormalities in liver function tests, nausea, parotitis, pseudo-obstruction (including colonic pseudo-obstruction), salivary gland pain, and vomiting.

**Genitourinary:**Decreased sexual activity, difficulty in micturition, erectile dysfunction, loss of libido, nocturia, and urinary retention.

**Hematologic:**Thrombocytopenia.

**Metabolic:**Gynecomastia, transient elevation of blood glucose or serum creatine phosphokinase, and weight gain.

**Musculoskeletal:**Leg cramps and muscle or joint pain.

**Oro-otolaryngeal:**Dryness of the nasal mucosa.

**Ophthalmological:**Accommodation disorder, blurred vision, burning of the eyes, decreased lacrimation, and dryness of eyes.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Clonidine Hydrochloride - FDA Drug Approval Details